Cromos Pharma began managing clinical research in Georgia in 2013. Since then, our Tbilisi-based operation has grown exponentially, managing numerous successful regional and global studies in a broad range of therapeutic areas.
|Lightning fast approval process. Georgia's regulatory approval process takes on average about two months.|
|Georgia's rapidly growing study-related workforce is well experienced in international, ICH GCP-compliant clinical trials.|
|Georgia's investment in the healthcare sector over the last decade has increased the number of medical facilities and in-patient beds.|
Most hospitals are well-equipped, and the staff is eager to participate in clinical research.
|Good recruitment potential due to an ethnically diverse population with treatment- naive patients in a range of therapeutic areas.|
Georgia's costs of clinical research are much lower than the US or Western Europe.
|Economic and political reforms have made Georgia an attractive and welcoming destination for international companies seeking to do business there.|
|Investigators and their patients are highly motivated to participate in trials as a way of accessing novel therapies not yet available through the national health system.|
Fourteen different therapeutic areas including:
Heart Disease, brain diseases, central nervous system diseases, neurological diseases, RNA infections and other viruses.
Georgia boasts an impressively rapid regulatory study approval process (<2 months from submission to study start). This rapid startup timeline, combined with a pool of skilled and professional medical staff, full compliance with ICH GCP standards and a solid reputation for producing high quality results make Georgia a very attractive prospect for sponsors.